CClinicalTrials.gg
Not yet recruitingNCT05963399CAREUPUpdated Mar 5, 2024

An Integrated Care Platform Based on the Monitoring of Older Individual Intrinsic Capacity for Inclusive Health (CAREUP)

An interventional study of CAREUP platform in Old Age, sponsored by Istituto Nazionale di Ricovero e Cura per Anziani. Not yet recruiting at 3 sites in 3 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by Istituto Nazionale di Ricovero e Cura per Anziani · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 9 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Study summary

The objective of this study is to assess the usability and acceptance of the CAREUP solution in improving the quality of life at home of the older adults. The CAREUP solution is a platform that collects data from different tools such as tablets, smartwatches, ambient sensors, iHealth weight scale, and Digital Hand Dynamometer.

.

Read the detailed description

The objective of this study is to assess the usability and acceptance of the CAREUP solution at home in primary (older adults), secondary (informal caregivers) and tertiary (doctors and geriatrics) end users. The CAREUP solution is a platform that collects data from different tools such as tablets, smartwatches, ambient sensors, iHealth weight scale, and Digital Hand Dynamometer. The study will comprehends two phases: a pre-pilot and pilot phases.The pre-pilot phase will test new user interfaces and games with 5 older adult (primary users) and 5 informal caregiver (secondary) in each site (Italy, Romania, Austria) for at least 1 week. This phase will only focus on primary endpoints (usability and acceptance). The pilot phase will investigate platform usability, acceptance and efficiency of developed Intrinsic Capacity (IC) evaluation algorithms, reliability and security. At least 30 primary and 15 secondary and some tertiary users (doctors and geriatrics) will be enrolled in each country (Italy, Romania, Austria) for 12 months. This phase will focus on both primary and secondary endpoints.

02

Conditions studied

  • Old Age

Keywords

  • ageing
  • older adults
  • artificial intelligence
  • informal caregiver
  • usability
  • acceptance
  • Intrinsic capacity
  • quality of life
  • wellbeing
  • loneliness
  • ICT-based solution
03

In context

Lead sponsor

Istituto Nazionale di Ricovero e Cura per Anziani is the lead sponsor of 41 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Live independently in their home in rural or urban areas;
  • In good physical and cognitive status;
  • Able to stand and walk unaided;
  • Availability to sign the Informed Consent;
  • Ability to use smartphones/tablets independently.

Exclusion criteria

Exclusion Criteria:

  • Use of active implant or not-implant medical devices;
  • Allergy to nickel components;
  • Lack of written informed consent;
  • Acute or untreated medical problems such as history of syncopal episodes, epilepsy and vertigo not controlled pharmacologically; serious dysfunction of the autonomic system; severe behavioural syndromes not compensated by drugs; concurrent neurological diseases; severe systemic diseases with life expectancy \< 1 year;
  • A myocardial infarction or stroke within 6 months;
  • Painful arthritis, spinal stenosis, amputation, painful foot lesions or neuropathy limiting balance and mobility;
  • Uncontrolled hypertension;
  • Pacemaker or implantable cardioverter defibrillator;
  • Diagnosis of mild and or/advanced Parkinson's disease or other neuromuscular disorder;
  • Diagnosis of mild and/or advance cognitive impairments
  • Metastatic cancer or immunosuppressive therapy;
  • Significant visual or hearing impairment
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    older adults

    Elderly adults who live independently in their own home in rural or urban areas.

    Device: CAREUP platform

Interventions

  • DeviceCAREUP platform

    The Experimental Group will test the CAREUP platform at home for 12 months.

06

What researchers measure

Primary outcomes

  1. Change in acceptability of the CAREUP platform

    Acceptability will be assess by an ad hoc structured questionnaire of 10 questions to collect data about like and dislike of the Careup platform.

    Time frame: baseline and 12 months later

  2. Change in usability of the CAREUP platform

    The System Usability Scale (SUS) is a reliable tool for measuring usability. It consists of a10 item questionnaire with five response options for respondents from 'Strongly agree' to 'Strongly disagree'.

    Time frame: baseline and 12 months later

Secondary outcomes

  1. Change in Physical Performance

    Short Physical Performance Battery (SPPB) is a short battery of tests designed to assess the function of the lower limbs. This scale consists of 3 different sections: balance assessment, evaluation of walking on 4 linear meters, evaluation of the ability to perform, for 5 consecutive times, the sit to stand from a chair, without using the upper limbs. The total scale score therefore has a range from 0 to 12. A total score below 10 indicates frailty and a high risk of disability and falls. The 1-point change in score from pre to post test is of clinical relevance.

    Time frame: baseline, 6 and 12 months later

  2. Change in Quality of Life

    The EuroQol-5D-5L (EQ-5D-5L) scale consists of five dimensions: mobility, independence, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, mild problems, moderate problems, severe problems and extreme problems. The participant is asked to indicate his/her health status by ticking the box corresponding to the most appropriate statement in each of the five dimensions. The numbers from the five dimensions can be combined into a 5-digit number that describes the health status of the participant. The numerals 1-5 have no arithmetic properties and should not be used as a cardinal score. In addition, there is the EQ Visual Analogue scale (EQ VAS).The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. The EQ-5D-5L now asks respondents to simply 'mark an X on the scale to indicate how your health is TODAY'.

    Time frame: baseline, 6 and 12 months later

  3. Change in Mood

    The 15-item Geriatric Depression Scale (GDS-15) assesses the current condition of the patient's mood. Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.

    Time frame: baseline, 6 and 12 months later

07

Study locations

3 sites
  • EURAG Austria
    Vienna, Austria
    • Eva Reither · Contact
    • Eva Reither · Principal investigator
  • IRCCS INRCA Hospital
    Ancona, 60127, Italy
  • Ana Aslan International Foundation
    Bucharest, Romania
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05963399
Lead sponsor
Istituto Nazionale di Ricovero e Cura per Anziani
Collaborators
European Union
Responsible party
Sponsor
First posted
Jul 27, 2023
Start date
Apr 30, 2024 (estimated)
Primary completion
Dec 14, 2024 (estimated)
Completion
Dec 14, 2024 (estimated)
Last update
Mar 5, 2024

Study contacts

Anna Rita Bonfigli
Contact
a.bonfigli@inrca.it
+390718003719
Vera Stara
study chair · IRCCS INRCA, Ancona, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion